Aankondiging • Jun 02
Biomica Completes Phase 1 Clinical Study of Bmc128 in Combination with Nivolumab Evogene Ltd. announced the successful completion of the first-in-human (FIH) Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, Biomica Ltd., in combination with Nivolumab in patients with advanced solid tumors, including melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC). The open-label, single-arm Phase 1 study enrolled 11 patients, with advanced solid tumors who had previously progressed following anti-PD-1 immunotherapy and was designed to evaluate the safety and tolerability of BMC128 in combination with Nivolumab. The treatment regimen included a two-week induction phase with BMC128 monotherapy, followed by 16 weeks of combination treatment with BMC128 and Nivolumab. Patients demonstrating clinical benefit were eligible to continue Nivolumab monotherapy for up to two years or until disease progression. The study successfully met its primary endpoint, demonstrating favorable safety and tolerability, with no dose-limiting toxicities observed. Preliminary clinical findings demonstrated early signs of anti-tumor activity. Five of the eleven treated patients achieved stable disease beyond the 16-week combination treatment period. Two patients remained on study through the full two-year follow-up period during Nivolumab maintenance therapy, while one patient achieved a partial response. In addition to clinical observations, translational analyses demonstrated biological signals consistent with the proposed mechanism of action of BMC128. Responding patients showed increased microbiome diversity, evidence of immune activation, and modulation of immune suppression-associated signatures. BMC128 is a rationally designed live bacterial therapeutic candidate developed to facilitate anti-tumor immune responses in patients receiving immune checkpoint inhibitors. The product consists of a defined consortium of bacterial strains selected based on Evogene's computational microbiome discovery platform and preclinical validation studies. Under the licensing agreement with Lishan Biotech, BMC128 is being further developed under the designation LS-LBP-002. Reported Earnings • May 21
First quarter 2026 earnings: EPS and revenues miss analyst expectations First quarter 2026 results: US$0.60 loss per share (further deteriorated from US$0.38 loss in 1Q 2025). Revenue: US$334.0k (down 86% from 1Q 2025). Net loss: US$5.88m (loss widened 127% from 1Q 2025). Revenue missed analyst estimates by 4.6%. Earnings per share (EPS) also missed analyst estimates by 122%. Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. Aankondiging • May 07
Evogene Ltd. to Report Q1, 2026 Results on May 20, 2026 Evogene Ltd. announced that they will report Q1, 2026 results Pre-Market on May 20, 2026 New Risk • Apr 17
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$14m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$14m free cash flow). Shareholders have been substantially diluted in the past year (81% increase in shares outstanding). Market cap is less than US$10m (US$9.98m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Revenue is less than US$5m (US$3.9m revenue). Reported Earnings • Mar 31
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: US$1.80 loss per share. Revenue: US$3.85m (down 31% from FY 2024). Net loss: US$14.2m (loss widened 6.9% from FY 2024). Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) also missed analyst estimates by 74%. Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Aankondiging • Mar 27
Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $4.478862 million. Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $4.478862 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 5,076,924
Price\Range: $0.8822 Price Target Changed • Mar 20
Price target decreased by 30% to US$1.75 Down from US$2.50, the current price target is provided by 1 analyst. New target price is 107% above last closing price of US$0.85. Stock is down 39% over the past year. The company posted a net loss per share of US$1.80 last year. Aankondiging • Feb 19
Evogene Ltd. to Report Q4, 2025 Results on Mar 05, 2026 Evogene Ltd. announced that they will report Q4, 2025 results on Mar 05, 2026 Aankondiging • Feb 10
Evogene Ltd. Appoints Prof. John J. Irwin and Prof. Dan T. Major to Its Scientific Advisory Board Evogene Ltd. announced the appointment of Prof. John J. Irwin of the University of California, San Francisco (UCSF), and Prof. Dan T. Major of Bar-Ilan University (BIU) to its Scientific Advisory Board. Prof. John J. Irwin is an Adjunct Professor in the Department of Pharmaceutical Chemistry at UCSF and a globally recognized leader in ligand discovery and virtual screening. He is the creator of foundational, open-access resources widely used across academia and industry, including ZINC, DOCK, SEA, and DUD-E. Prof. Irwin's work has been cited over 35,000 times and has had a lasting impact on modern drug discovery through data-driven and collaborative science. Prof. Dan T. Major is a Professor of Chemistry at Bar-Ilan University and a leading expert in multiscale molecular modeling. His research integrates quantum mechanics, artificial intelligence, and biotechnology to accelerate drug discovery, ag-chemical development, and materials design. Prof. Major is a pioneer in hybrid QM/MM simulations and the developer of EnzyDock and RxnNet, with more than 150 peer-reviewed publications and multiple prestigious awards recognizing the translational impact of his work. Aankondiging • Jan 16
Evogene Ltd. Announces CFO Changes Evogene Ltd. reported changes in its management. Mr. Yaron Eldad, the Company’s Chief Financial Officer, notified his resignation from his position effective as of Mach 31, 2026. The resignation of Mr. Eldad was due to personal reasons and was not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company. Ms. Polina Ravzin, the Company’s VP Finance, will continue in such position and will also assume the responsibilities of the CFO. Ms. Ravzin has served as the Company’s VP Finance from 2022. Prior to joining the Company, Ms. Ravzin served as controller and assistant to the CFO at DSIT Solutions Ltd. and Acorn Energy Inc. Aankondiging • Nov 06
Evogene Ltd. to Report Q3, 2025 Results on Nov 20, 2025 Evogene Ltd. announced that they will report Q3, 2025 results on Nov 20, 2025 Aankondiging • Jul 29
Evogene Ltd. to Report Q2, 2025 Results on Aug 19, 2025 Evogene Ltd. announced that they will report Q2, 2025 results on Aug 19, 2025 Aankondiging • Jun 18
Evogene Ltd., Annual General Meeting, Aug 11, 2025 Evogene Ltd., Annual General Meeting, Aug 11, 2025. Location: 13 gad feinstein street, park rehovot, rehovot, Israel Aankondiging • Jun 10
Evogene Ltd. Announces Completion of First-In-Class Foundation Model Forgenerative Molecule Design, Developed in Collaboration with Google Cloud Evogene Ltd. announced the completion of its generative AI foundation model, version 1.0, for small molecule design, developed in collaboration with Google Cloud. The new model expands the existing capabilities of ChemPass AI, Evogene's tech-engine for small molecule discovery and optimization, by addressing one of the core challenges faced by both the pharmaceutical and agriculture industries: identifying novel small molecules that meet multiple complex product criteria. In both pharma and agriculture, successful product development depends on identifying molecules that meet complex performance criteria while also being patentable. Traditional discovery methods typically address these challenges sequentially, a process that reduces success probability. This breakthrough paves the way for creating highly potent, synthesizable, and patentable molecules across life-science products. Built on a large dataset of approximately 38 billion molecular structures, the model was trained and deployed using Google Cloud's advanced AI infrastructure, including high-performance GPUs and scalable storage. The result is a foundation model that not only powers Evogene's ChemPass AI but will also provide a scalable base for future enhancements. Evogene also announces that development is already underway on version 2.0 of its generative AI foundation models, with a focus on enhanced flexibility for multi-parameter optimization. The updated version will incorporate predefined, customized parameters tailored to therapeutic contexts or specific agriculture requirements. It will enable ChemPass AI to better balance complex real-world constraints, such as efficacy, toxicity, and stability, significantly improving its ability to generate molecules optimized for clinical, commercial, and regulatory success. Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its four subsidiaries including: Biomica Ltd. - developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI; Lavie Bio - developing and commercially advancing, microbiome based ag-biologicals powered by MicroBoost AI; AgPlenus Ltd. - developing next generation ag-chemicals for effective and sustainable crop protection powered by ChemPass AI; and Casterra Ag - developing and marketing superior castor seed varieties producing high yield and high-grade oil content, on an industrial scale for the biofuel and other industries powered by GeneRator AI. Aankondiging • May 08
Evogene Ltd. to Report Q1, 2025 Results on May 21, 2025 Evogene Ltd. announced that they will report Q1, 2025 results on May 21, 2025 Aankondiging • Feb 20
Evogene Ltd. to Report Q4, 2024 Results on Mar 06, 2025 Evogene Ltd. announced that they will report Q4, 2024 results on Mar 06, 2025 Aankondiging • Nov 07
Evogene Ltd. to Report Q3, 2024 Results on Nov 21, 2024 Evogene Ltd. announced that they will report Q3, 2024 results on Nov 21, 2024 Aankondiging • Sep 17
Evogene Ltd. Announces Executive Changes Evogene Ltd. reported changes in its management team: As part of an organizational restructuring, Mr. Mark Kapel, the Company's Chief Technology Officer, will conclude his employment with Evogene, effective October 31, 2024. Evogene expresses its gratitude to Mr. Kapel for his contributions during his tenure. Mr. Kapel will continue to provide consulting services to Evogene. The Chief Technology Officer's responsibilities will be divided between the Evogene's VP Computational Platform, Dr. Ilia Zhidkov, and the VP Experimental Research Center, Dr. Silvia Shaked, both of whom have been with Evogene for the past 13 years. In addition, Dr. Gabi Tarcic, will be appointed as Evogene's VP Product, effective September 22, 2024. Dr. Tarcic has extensive experience in research and development projects and as a senior executive. Since 2012 Dr. Tarcic has served in various positions at Fore Biotherapeutics (formerly NovellusDx Israel), most recently as its Chief Technology Officer. Dr. Tarcic holds a Ph.D. from The Weizmann Institute of Science, Rehovot, Israel. Aankondiging • Aug 12
Evogene Ltd. to Report Q2, 2024 Results on Aug 22, 2024 Evogene Ltd. announced that they will report Q2, 2024 results on Aug 22, 2024 Aankondiging • May 11
Evogene Ltd. to Report Q1, 2024 Results on May 23, 2024 Evogene Ltd. announced that they will report Q1, 2024 results on May 23, 2024 Aankondiging • May 01
Evogene Ltd., Annual General Meeting, Jun 06, 2024 Evogene Ltd., Annual General Meeting, Jun 06, 2024, at 15:00 Israel Standard Time. Location: offices at 13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel Rehovot Israel Agenda: To discuss Re-election of each of (a) Ms. Sarit Firon, (b) Dr. Adrian Percy, (c) Mr. Leon Y. Recanati, (d) Prof. Oded Shoseyov, (e) Mr. Dan Falk, and (f) Mr. Nir Nimrodi; as a director of the Company, until the Company’s next annual general meeting of shareholders and until his or her successor is duly elected and qualified; to approve a reverse share split of the Company’s ordinary shares; to Adoption of a new compensation policy for the Company’s office holders; to Approval of the grant of options to purchase of the Company’s Ordinary Shares; and to Approval of the re-appointment of Kost Forer Gabbay & Kasierer, registered public accounting firm, a member firm of Ernst & Young Global, as the Company’s independent registered public accounting firm for the year ending December 31, 2024 and until the Company’s next annual general meeting of shareholders, and the authorization of the Board or the audit committee thereof to fix such accounting firm’s annual compensation. Aankondiging • Mar 30
Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $7.3 million. Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $7.3 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Transaction Features: At the Market Offering Aankondiging • Mar 21
Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification Evogene Ltd. reported that the Company received a letter (the "Letter") from the Nasdaq Stock Market LLC ("Nasdaq"), indicating that the Company is currently not in compliance with Nasdaq Rule 5550(a)(2), as the Company's closing bid price for its ordinary shares has been below $1.00 per share for the last 30 consecutive business days. The Nasdaq Stock Market Rules provide the Company with an additional period of 180 calendar days to regain compliance. According to the Letter, the Company has until September 16, 2024, to regain compliance with the minimum bid price requirement. The Company will regain compliance, if at any time during this 180-day period, the closing bid price of its ordinary shares is at least $1.00 for a minimum period of ten consecutive business days, in which case the Company will be provided with a written confirmation of compliance from Nasdaq and this matter will be closed. If the Company does not demonstrate compliance (with the bid price requirement or with any other listing requirements) prior to the end of the 180-day period ending September 16, 2024, the Nasdaq's staff will notify the Company that its ordinary shares will be subject to delisting. It is noted that Evogene's continued listing on Nasdaq remains a key priority for the Company. Should the situation not resolve itself over the above-mentioned timeframe, the Company intends to consider other available options to cure the deficiency and regain compliance with the minimum bid requirement within the compliance period, including potentially approving a reverse share split among other alternatives. The Letter from Nasdaq has no immediate effect on the Company's Nasdaq listing or the trading of its ordinary shares on Nasdaq, and during the aforementioned cure period, the Company's ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol "EVGN". It is further noted that the Letter from Nasdaq has no bearing on Evogene's listing on the Tel Aviv Stock Exchange, where its ordinary shares are traded under the ticker symbol "EVGN". Reported Earnings • Mar 08
Full year 2023 earnings: EPS and revenues exceed analyst expectations Full year 2023 results: US$0.52 loss per share (improved from US$0.65 loss in FY 2022). Revenue: US$5.64m (up 237% from FY 2022). Net loss: US$23.9m (loss narrowed 10% from FY 2022). Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 8.0%. Revenue is forecast to grow 55% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings. Aankondiging • Feb 27
Evogene Ltd. to Report Q4, 2023 Results on Mar 07, 2024 Evogene Ltd. announced that they will report Q4, 2023 results on Mar 07, 2024 Aankondiging • Dec 19
Casterra Ag Ltd., a subsidiary of Evogene Ltd Announces Executive Changes, Effective January 1, 2024 Casterra Ag Ltd., a subsidiary of Evogene Ltd. announced the appointment of Mr. Yoash Zohar as new CEO, as of January 1, 2024, to lead the company's expansion efforts. Considering Casterra's rapid growth and its continued prospects for development, this nomination aims to strengthen its leadership and positioning in the industry. Casterra entered a new phase in its life cycle of mass production of castor seeds to support the demand for its elite varieties, addressing the bio-diesel industry's growing needs. To this end, Casterra needs to significantly increase its castor seed production capacity through existing and new subcontractors in target-market locations. Mr. Yoash Zohar, the newly appointed CEO, brings extensive experience in global agricultural projects, particularly in Africa, along with skills in castor bean cultivation. His professional qualifications align with Casterra's current focus on establishing a robust seed production system within target geographical territories to support company's expansion. Casterra's current CEO Mr. Eyal Ronen, who also serves as Evogene's EVP of Business Development, led Casterra's activities for the past year and a half and will now resume full-time position as EVP BD. Mr. Eyal Ronen will continue to serve as a director on Casterra's Board and support company management in successfully reaching its goals. Casterra has also significantly expanded its team, including experts in research and development, seed production, and customer support. This expansion is expected to drive innovation in the company's product offerings, support the anticipated seed production increase, and enhance customer service. New Risk • Nov 21
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 23% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$8.6m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (US$32.9m market cap). Reported Earnings • Nov 17
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Third quarter 2023 results: US$0.081 loss per share (improved from US$0.16 loss in 3Q 2022). Revenue: US$3.77m (up US$3.30m from 3Q 2022). Net loss: US$3.98m (loss narrowed 39% from 3Q 2022). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 49%. Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. Aankondiging • Nov 03
Evogene Ltd. to Report Q3, 2023 Results on Nov 15, 2023 Evogene Ltd. announced that they will report Q3, 2023 results on Nov 15, 2023 Reported Earnings • Aug 18
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2023 results: US$0.17 loss per share (improved from US$0.21 loss in 2Q 2022). Net loss: US$7.02m (loss narrowed 20% from 2Q 2022). Revenue missed analyst estimates by 26%. Earnings per share (EPS) exceeded analyst estimates by 2.9%. Revenue is forecast to grow 62% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. New Risk • Aug 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$16m net loss in 3 years). Revenue is less than US$5m (US$2.1m revenue). Market cap is less than US$100m (US$41.0m market cap). Aankondiging • Aug 01
Evogene Ltd. to Report Q2, 2023 Results on Aug 17, 2023 Evogene Ltd. announced that they will report Q2, 2023 results on Aug 17, 2023 Aankondiging • Jul 26
Evogene Ltd 's ChemPass AI Tech-Engine is Introduces with New Breakthrough Machine Learning Technology for Target-Protein Discovery Evogene Ltd. announced the latest addition to its ChemPass AI tech-engine - a breakthrough technology for target-protein discovery. The integration of TargetSelector, a new application that streamlines target-protein discovery for active molecule identification, assists researchers in finding suitable target proteins for new products while reducing development time, resources and most importantly, increasing the probability of success. Proteins play a fundamental role in a wide array of biological processes and serve as the primary targets for developing innovative therapeutics, ag-chemical, ag-biological, and other life science solutions. The precise identification of these protein targets is pivotal in advancing research and discovery across various domains, including pharmaceuticals, agriculture, and environmental applications. The challenge of finding a target-protein that is novel, safe, and druggable from the thousands of proteins in a relevant organism is enormous. Leveraging predictive machine learning algorithms and genomic data, users gain valuable insights into product requirements such as homology, druggability, essentiality, and biological pathways, efficiently narrowing down the list of potential target-protein, thus optimizing the discovery process. Aankondiging • Jul 22
Biomica Ltd. Reports Interim Positive Results from Pre-Clinical Studies in its IBS Program Biomica Ltd. reported interim positive results from pre-clinical studies in its IBS program. The pre-clinical work was performed in collaboration with the lab of Prof. Kara Gross Margolis, Associate Director for Clinical and Translational Research for the New York University Pain Research Center and an Associate Professor in the Department of Molecular Pathobiology in the NYU College of Dentistry and the Department of Pediatrics at NYU Grossman School of Medicine. In these studies, Biomica tested two candidate therapeutic consortia of live bacterial strains, BMC426 and BMC427. Treatment with these drug candidates effectively reduced visceral pain, a major symptom of IBS. Irritable bowel syndrome, or IBS, is a chronic digestive system disorder estimated to affect 4.1% of the worldwide population1. IBS-affected individuals suffer from abdominal pain, bloating, and abnormal bowel movements; that often affect their daily functioning and quality of life. Current standard therapies for IBS are limited, particularly in relation to IBS-associated abdominal pain. Studies have pointed to associations between alterations in the gut microbiome and IBS, suggesting microbiome involvement in developing IBS symptoms2. BMC426 and BMC427 were designed based on their functional capabilities, utilizing data collected from IBS patients through research conducted at the University of North Carolina (UNC) Chapel Hill by Prof. Yehuda Ringel, Co-Founder and Chief Scientific Officer of Biomica. The data was analyzed in silico using Biomica's PRISM system, a proprietary computational platform powered by Evogene's MicroBoost AI tech-engine. Numerous functional capabilities of BMC426 and BMC427 have been successfully validated in relevant in-vitro models. Biomica is announcing positive results observed in its in-vivo pre-clinical work, which aimed to evaluate the potential of BMC426 and BMC427 in treating IBS. New Risk • Jun 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$23m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (US$2.1m revenue). Market cap is less than US$100m (US$34.2m market cap). Aankondiging • May 06
Evogene Ltd., Annual General Meeting, May 11, 2023 Evogene Ltd., Annual General Meeting, May 11, 2023, at 15:00 Israel Standard Time. Location: 13 Gad Feinstein Street Park Rehovot Rehovot Israel Aankondiging • May 05
Evogene Ltd. to Report Q1, 2023 Results on May 18, 2023 Evogene Ltd. announced that they will report Q1, 2023 results on May 18, 2023 Reported Earnings • Mar 11
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: US$0.65 loss per share (improved from US$0.69 loss in FY 2021). Net loss: US$26.6m (loss narrowed 4.2% from FY 2021). Revenue exceeded analyst estimates by 6.7%. Earnings per share (EPS) also surpassed analyst estimates by 14%. Revenue is forecast to grow 92% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 21
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: US$0.16 loss per share (improved from US$0.19 loss in 3Q 2021). Net loss: US$6.54m (loss narrowed 14% from 3Q 2021). Revenue exceeded analyst estimates by 65%. Earnings per share (EPS) also surpassed analyst estimates by 19%. Revenue is forecast to grow 108% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Price Target Changed • Nov 16
Price target decreased to US$6.00 Down from US$6.67, the current price target is provided by 1 analyst. New target price is 733% above last closing price of US$0.72. Stock is down 69% over the past year. The company posted a net loss per share of US$0.69 last year. Reported Earnings • Sep 02
Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2022 results: US$0.21 loss per share (down from US$0.15 loss in 2Q 2021). Net loss: US$8.82m (loss widened 42% from 2Q 2021). Revenue exceeded analyst estimates by 41%. Earnings per share (EPS) missed analyst estimates by 11%. Over the next year, revenue is forecast to grow 833%, compared to a 41% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Reported Earnings • May 28
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: US$0.20 loss per share (down from US$0.17 loss in 1Q 2021). Net loss: US$8.28m (loss widened 25% from 1Q 2021). Revenue missed analyst estimates by 23%. Earnings per share (EPS) also missed analyst estimates by 11%. Over the next year, revenue is forecast to grow 567%, compared to a 40% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Price Target Changed • Apr 27
Price target decreased to US$10.33 Down from US$11.33, the current price target is an average from 3 analysts. New target price is 875% above last closing price of US$1.06. Stock is down 77% over the past year. The company posted a net loss per share of US$0.69 last year. Board Change • Mar 29
High number of new directors Scientific Advisor Eran Segal was the last director to join the board, commencing their role in 2022. Price Target Changed • Mar 12
Price target decreased to US$10.33 Down from US$11.33, the current price target is an average from 3 analysts. New target price is 740% above last closing price of US$1.23. Stock is down 78% over the past year. The company posted a net loss per share of US$0.69 last year. Reported Earnings • Mar 11
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: US$0.69 loss per share (up from US$0.83 loss in FY 2020). Net loss: US$27.8m (loss widened 19% from FY 2020). Revenue exceeded analyst estimates by 51%. Earnings per share (EPS) missed analyst estimates by 3.7%. Over the next year, revenue is forecast to grow 161%, compared to a 61% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Board Change • Feb 04
High number of new directors Scientific Advisor Eran Segal was the last director to join the board, commencing their role in 2022. Executive Departure • Dec 01
Chief Executive Officer of AgPlenus Ltd. Douglas Eisner has left the company During their tenure, earnings grew by 34% annually compared to the industry average of 11%. On the 1st of December, Douglas Eisner left the company after 1.2 years in the role. We don't have any record of a personal shareholding under Douglas' name. Douglas is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 2.67 years. Reported Earnings • Nov 19
Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 3Q 2020) Third quarter 2021 results: Net loss: US$7.61m (loss widened 59% from 3Q 2020). Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 5% per year. Board Change • Nov 03
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 4 experienced directors. 1 highly experienced director. Independent Director Leon Recanati is the most experienced director on the board, commencing their role in 2005. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 12
Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.17 loss in 2Q 2020) Second quarter 2021 results: Net loss: US$6.21m (loss widened 47% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 4% per year. Reported Earnings • May 27
First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.24 loss in 1Q 2020) First quarter 2021 results: Net loss: US$6.60m (loss widened 6.0% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 6% per year. Reported Earnings • Apr 05
Full year 2020 earnings released: US$0.83 loss per share (vs US$0.70 loss in FY 2019) Full year 2020 results: Net loss: US$23.4m (loss widened 29% from FY 2019). Products in clinical trials Phase I: 6 Phase II: 1 Post-clinical trial products Approved (during full year): 1 Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Feb 12
Price target raised to US$15.00 Up from US$9.00, the current price target is provided by 1 analyst. The new target price is 51% above the current share price of US$9.94. As of last close, the stock is up 558% over the past year. Is New 90 Day High Low • Feb 05
New 90-day high: US$7.68 The company is up 183% from its price of US$2.71 on 06 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period. Is New 90 Day High Low • Jan 15
New 90-day high: US$5.95 The company is up 56% from its price of US$3.82 on 16 October 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 19% over the same period. Is New 90 Day High Low • Dec 29
New 90-day high: US$5.63 The company is up 38% from its price of US$4.08 on 29 September 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 19% over the same period. Is New 90 Day High Low • Dec 11
New 90-day high: US$4.31 The company is up 102% from its price of US$2.13 on 11 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period. Reported Earnings • Nov 20
Third quarter 2020 earnings released: US$0.18 loss per share Third quarter 2020 results: Net loss: US$4.79m (loss widened 13% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Oct 06
New 90-day high: US$4.16 The company is up 304% from its price of US$1.03 on 08 July 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 5.0% over the same period. Is New 90 Day High Low • Sep 19
New 90-day high: US$3.09 The company is up 209% from its price of US$1.00 on 19 June 2020. The American market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period.